Page 14 - Genentech News Today

MAINZ, Germany, April 22, 2024 -- BioNTech SE will announce its financial results for the first quarter 2024 on Monday, May 6, 2024. Additionally, the Company will host a conference call and...

Despite financial boons to the region’s artificial intelligence and biotechnology sector, accompanying jobs in the county are slow to pick up so far this year, as layoffs and continuously high

The approval makes alectinib the first ALK inhibitor approved for early-stage NSCLC.

The analysis also found the therapy has a manageable safety profile.

2024 ANNUAL GENERAL MEETING OF SHAREHOLDERS PROQR THERAPEUTICS N.V. Explanatory Notes to the Agenda ProQR Therapeutics N.V. | Zernikedreef 9...

In this article, we discuss the 25 richest billionaires in healthcare industry.

The Women In The NAACP Oakland Branch is proud to announce the upcoming “Total You - Mind, Body, and Spirit Women's Health Forum” scheduled for April 27 at Acts Full Gospel Church. Running from 9 a.m.-2 p.m. at 1034 66th Ave., this forum aims to provide an empowering platform for women to engage in discussions, gain knowledge, and access resources pertaining to their health and well-being. | Special to The Post The Women In The NAACP Oakland Branch is proud to announce the upcoming “T...

The FDA has approved alectinib as adjuvant treatment in select patients with ALK-positive non–small cell lung cancer.

LiveNews Provides news reports of information as it happens in real time of politics, business, the economy and also reports on global issues and events from a New Zealand viewpoint.

The ALK inhibitor reduced the risk of recurrence or death by 76% versus chemotherapy